Text Size




National Stroke Association
Homepage | Forward to a Friend | Make a Donation
Professional Education Newsletter

December 2012

Clinical Trial to Test Nine-Hour Thrombolytic

Doctor with patient photo

Desmoteplase, a new thrombolytic for treating acute ischemic stroke, is in phase III trials at more than 72 sites across the U.S. by H. Lundbeck A/S, a Danish pharmaceutical company. Desmoteplase is intended to be injected within three to nine hours after the onset of ischemic stroke symptoms. 

The trial is currently recruiting patients. Learn more.

The content of this enewsletter does not imply National Stroke Association's endorsement of any product, treatment, service or entity. National Stroke Association has no affiliation with any specific clinical trials.

Controversies in Stroke Care

Photo of doctors

Register for the second and third accredited webinars in the Controversies in Stroke Care series.

Webinar 2: Rehabilitation
Wednesday, Jan. 23, 2013
noon EST

Register for this webinarThis webinar will explore the divergent opinions regarding rehabilitative therapies for stroke survivors. Should the focus be on intensity of activities or quality of performance? What is the best timing for therapeutic intervention? Which delivery methods are optimal?

Pamela S. Roberts, PhD, CPHQ, Cedars-Sinai Medical Center, Los Angeles, will moderate. Dr. Elliot J. Roth, Rehabilitation Institute of Chicago and Dr. Richard D. Zorowitz, Johns Hopkins Bayview Medical Center, Baltimore, will offer the differing points of view.

Supported by an independent educational grant from Genentech, Inc. and supported by Penumbra, Inc.

Register for this webinarWebinar 3: Acute Interventions
Thursday, Feb. 28, 2013
noon EST

The third and final webinar in the Controversies in Stroke Care series will be a discourse on acute interventions in stroke treatment.

The use of interventional techniques for acute stroke is a rapidly evolving field. This webinar will include discussions about trials and studies for acute interventional treatments. What does the literature and evidence show? What does expert opinion and common sense indicate?

The panel will consist of Dr. Richard Latchaw, UC Davis Medical Center, Dr. Robert Ferguson, MetroHealth Medical Center, and Dr. Mark Alberts, UT Southwestern.

Supported by an independent educational grant from Genentech, Inc. and supported by Penumbra, Inc.

arrow iconView the first accredited webinar in the Controversies series, Redefining Exclusion/Inclusion Criteria for IV tPA Use.



Logo for The Business of Stroke

Comprehensive Stroke Center Webinar Series

Learn about The Joint Commission’s standards for the new Comprehensive Stroke Center (CSC) designation, best care practices for all stroke patients and the experience of one recently certified center, in three archived webinars.

Supported by an educational grant from Stryker.

Tell a Friend


Share on Facebook

Powered By Blackbaud Unsubscribe | Forward to a Friend | Visit Our Website    Follow Us on Twitter    Join Us on Facebook

9707 E. Easter Lane, Suite B, Centennial, CO 80112
1-800-STROKES (787-6537) | fax: 303-649-1328

National Stroke Association © 2014 All rights reserved.